Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared Elad Sharon’s, Clinical and Translational Director of Immunotherapy Toxicity Program at Dana-Farber Cancer Institute, post on X, adding:
“Median PFS with standard first line treatments in HER2+ MBC: 4 months with chemo (2001), 40 months with T-DXd/P (2025). Same disease, improved understanding, better treatments!”
Quoting Elad Sharon’s post on X:
“May all cancers have such an incredible trajectory in their outcomes! Incredible results! A tribute to all of our collective efforts in the biomedical enterprise!”
Other articles featuring Paolo Tarantino and Elad Sharon on OncoDaily.
